• ARS Pharmaceuticals named Donn Casale president, effective June 1, 2026.
• Casale will run global commercial operations and growth infrastructure as company prepares for expansion, including planned move into chronic spontaneous urticaria.
• Richard Lowenthal remains chief executive officer.
• Casale was most recently chief commercial officer at Dynavax Technologies, where he built U.S. commercial infrastructure and scaled HEPLISAV-B to more than $300 million in annualized revenue and over 50% U.S. market share.
• He previously held marketing and commercial operations leadership roles at Depomed, now Assertio Therapeutics, following 14 years at Merck in U.S. vaccines sales leadership and commercial strategy roles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130800PRIMZONEFULLFEED9719188) on May 13, 2026, and is solely responsible for the information contained therein.